Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
He built a MERS treatment in 6 months and then the best Ebola drug. Now Christos Kyratsous turns his sights on ...
6 years ago
R&D
In Focus
As sickle cell patients find new options, NEA-founded Imara pitches mid-stage alternative for $86M IPO
6 years ago
Financing
RA joins global syndicate to back a $98M round for CANbridge
6 years ago
Financing
China
Drug discovery in HD: Oxford spinoff's mass spectrometry approach scores fresh funding
6 years ago
Financing
Startups
China approves flu drug being touted as a potential coronavirus treatment amid a rush of clinical studies
6 years ago
China
Coronavirus
FDA goes on high alert as coronavirus raises threat to drug manufacturing and clinical trials grind to a halt
6 years ago
R&D
FDA+
Warren Buffett gets a double take as the investment powerhouse settles on its first biotech investment
6 years ago
R&D
The top 100 biopharma venture investors at the megabillions deal table
6 years ago
Financing
Former Novartis exec pleads guilty to generic price fixing
6 years ago
Pharma
Palleon's first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO
6 years ago
Peer Review
New entries, price hikes spur changes among the 20 most expensive drugs — though not the kind politicians like to ...
6 years ago
Pharma
AstraZeneca sweeps two cancer drugs to the scrap heap; Epizyme nabs priority review for second rare cancer NDA
6 years ago
News Briefing
If you were a cancer patient, where would you rather be — the United States or Europe?
6 years ago
R&D
AstraZeneca's Chinese investment bank partner raises $229M for its own new fund — and it's all about the ...
6 years ago
R&D
Coronavirus
Coronavirus outbreak clouds AstraZeneca's Q4 results and 2020 outlook
6 years ago
R&D
Pharma
The list of the 11 blockbusters-to-be in line for a 2020 launch highlight agony and ecstasy of drug R&D
6 years ago
Pharma
Internal FDA emails reveal how price, Sanders’ pressure played a role in competitor’s approval, Catalyst claims
6 years ago
FDA+
Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine
6 years ago
People
R&D
8 years after its OK, Eisai yanks its flailing obesity drug from the market after FDA flagged higher cancer rate
6 years ago
Pharma
FDA+
Elanco grabs $140M in deal with French pharma company; Another company announces a coronavirus vaccine hunt
6 years ago
News Briefing
Coronavirus
The White House review of drug prices: Don't hate the player — hate the game
6 years ago
R&D
Seattle Genetics gets another drug close to the finish line
6 years ago
R&D
Roche scores its first PD-L1 win in China, going straight for SCLC niche
6 years ago
China
Pharma
After FDA hold and trial failure, Ipsen writes down its big acquisition — but they're not giving up
6 years ago
Pharma
First page
Previous page
857
858
859
860
861
862
863
Next page
Last page